Back to Treatments

Treatment

Pembrolizumab (for recurrent/metastatic NPC)

1
Conditions
3
Trials
5,000
Participants
45%
Average Safety

Condition Evidence

Nasopharynx cancer

3 trials · 5,000 participants

65% effectiveness · 45% safety
Pembrolizumab (for recurrent/metastatic NPC) | DFDA